Pfizer Releases Caduet Crucial Trial Data
In the trial Caduet (amlodipine besylate/atorvastatin calcium) was associated with a reduced calculated 10-year risk of coronary heart disease (CHD) based on a Framingham risk assessment model. Pfizer
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
Quotient Bioresearch’s The Old Glassworks is expected to produce radiolabelled compounds for use in both pre-clinical and clinical settings, for its pharmaceutical, biotechnology and agrochemical clients, offering a
OrbusNeich said that, in the investigator-initiated, single center, all-comers POTENT (Paclitaxel-eluting balloon and bio-engineered progenitor cell-attracting stainless steel stent in percutaneous treatment of coronary artery stenosis) registry, 32%